Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004601534 | SCV003756293 | uncertain significance | not specified | 2024-03-26 | criteria provided, single submitter | clinical testing | The c.388G>C (p.V130L) alteration is located in exon 3 (coding exon 2) of the VCX3A gene. This alteration results from a G to C substitution at nucleotide position 388, causing the valine (V) at amino acid position 130 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV001795739 | SCV005207932 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Laboratory of Diagnostic Genome Analysis, |
RCV001795739 | SCV002035416 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001795739 | SCV002038415 | likely benign | not provided | no assertion criteria provided | clinical testing |